Lumen Health Tech Company Reveals New Data About Metabolism Training
7.1.2021 13:32:00 EET | Business Wire | Press release
Lumen, a health technology company at the forefront of metabolic health, has uncovered new data that reveals how training your metabolism is the greatest contributor to sustainable health and weight loss, not crash dieting.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210107005400/en/
Lumen metabolism insights (Photo: Lumen)
The data analysis is based on 1 million metabolism measurements throughout 2020, as Lumen data scientists have discovered that metabolic flexibility, or the body's ability to efficiently switch between carbs and fats as an energy source, is the key to optimal health.
By focusing on optimising their metabolism, users were able to increase metabolic flexibility by 33%. Two-thirds also reported losing weight at a rate of 2 pounds per week on a consistent basis.
On the nutrition end, users successfully completed an average of 12 hour fasts and mostly followed their personalised nutrition plan according to what their metabolism measurement prescribed. The top 2% were able to start their day in a state of burning fat for 4 consecutive days. Naturally, users also became more active and completed an average of 1000 more steps a day, and slept at least 7 hours.
That's equivalent to walking to the supermarket, doing one weekly workout at home, eating a couple carb servings per meal with room for low-carb snacks, and eating dinner by 7pm followed by a decent night of sleep.
Research (Calcada et al, Gormsen et al) finds that people with good metabolic flexibility:
- Are in a better position to gain muscle and perform better during workouts
- Find it easier to lose weight and maintain it; and
- Are at lower risk of developing obesity, diabetes and metabolic disorders.
"Understanding how your body reacts to what you eat and how you exercise is crucial to training your metabolism. The base of performance, health and weight loss starts with your metabolism- and we are able to see the data of users worldwide improving their health every day just by being more aware of their body," said Barak Alon, head of data at Lumen.
In an effort to raise awareness for metabolic health and its many benefits, Lumen is launching a campaign entitled "New year, new metabolism" through a resource center with a downloadable health kit including extensive insights on nutrition and exercise to optimise metabolic health and flexibility.
About Lumen
Lumen is a device and app that measures your metabolism in a single breath through a complex algorithm and provides daily personalised nutrition based on your metabolic data. At Lumen, we believe that a healthy metabolism is the key to better health, and that everyone can attain it with a little help from Lumen.
Founded in 2014 by scientists and experienced entrepreneurs, Lumen is the biggest metabolic measurement platform in the world, with over 1,000,000 measurements per month.
Our technology provides individuals with new metrics on metabolism and a system to keep them accountable so they can achieve their health and wellness goals and prevent long-term chronic illness by improving their metabolic health.
Scientific Validation
Lumen can provide numerous insights about the metabolism of an individual, as well as valuable scientific data to increase knowledge of metabolic flexibility and nutrition. In a study conducted by San Francisco State University, Lumen has been validated to meet the gold standard for metabolic measurement.
Availability
The Lumen device is available at Lumen.me, currently priced at £299 with an MSRP of £349. The device comes equipped with a travel case, charging dock, USB-C Cable, and Premium Customer Support. Users can download the app for free on the Apple App Store and on Google Play.
Follow us on twitter.com/LumenMetabolism, facebook.com/Lumen.me/, instagram.com/lumen.me/, youtube.com/c/Lumendotme
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005400/en/
Contact information
Media contact: Kyla Blumenfeld, press@lumen.me
+972548161939
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
